Resilience is a technology company.
Resilience has raised $826.0M across 4 funding rounds.
Resilience has raised $826.0M in total across 4 funding rounds.
Resilience (National Resilience, Inc.) is a technology-focused biomanufacturing company and contract development and manufacturing organization (CDMO) dedicated to broadening access to complex medicines like biologics, vaccines, cell and gene therapies, and nucleic acids.[2][3][6] It builds a sustainable network of high-tech, end-to-end manufacturing facilities across North America (and expanding internationally) to produce treatments quickly, safely, and at scale, while protecting biopharmaceutical supply chains from disruptions.[2][4][6] Serving biotech firms of all sizes—from small innovators to large players—Resilience solves critical bottlenecks in biomanufacturing by offering flexible, adaptive facilities with regulatory expertise, advanced AI-driven platforms, and capacity that scales with client needs.[3][5][6] The company has shown strong growth momentum, including network expansions adding hundreds of jobs (e.g., in Cincinnati), recognition on BioSpace's 2025 Best Places to Work list, and backing from top VCs like ARCH Venture Partners and 8VC.[3][4][5]
Founded in 2020 amid the COVID-19 pandemic, Resilience emerged to address gaps in biomanufacturing capacity exposed by the global health crisis, with a mission to advance manufacturing technologies and redefine partnerships between CDMOs and innovators.[2][5][6] The founding executive team comprises industry veterans, supported by prominent VC firms ARCH Venture Partners and 8VC, enabling rapid scaling through strategic acquisitions of manufacturing and development facilities across North America.[4][5] Key early traction came from upgrading digital, quality, and capacity at these sites, instantly providing clients access to high-demand modalities and establishing Resilience as a leader in under four years.[5]
Resilience rides the wave of explosive growth in advanced therapies—cell/gene therapies, nucleic acids—where scientific breakthroughs outpace manufacturing capabilities, exacerbated by supply chain vulnerabilities revealed during pandemics.[2][6] Its timing is ideal post-2020, capitalizing on market forces like regulatory pressures for resilient biopharma supply chains, rising demand for scalable production, and investor focus on life sciences infrastructure.[4][5] By influencing the ecosystem through tech upgrades, international expansion, and VC-backed innovation, Resilience enables faster patient access to therapies, reduces disruption risks, and sets a new standard for CDMOs as strategic partners rather than mere service providers.[3][5][6]
Resilience is poised for accelerated growth through further facility expansions, international scaling, and deployment of AI/next-gen platforms to handle surging demand for complex modalities.[3][5][6] Trends like AI-driven biomanufacturing, personalized medicine, and global supply chain fortification will shape its trajectory, potentially amplifying its influence as a go-to CDMO for disruptive biotechs. As it evolves from rapid builder to ecosystem shaper, Resilience exemplifies how technology can future-proof essential medicines, turning vulnerability into scalable strength.
Resilience has raised $826.0M in total across 4 funding rounds.
Resilience's investors include Heartcore Capital, HV Capital, HV Holtzbrinck Ventures, Picus Capital, White Star Capital, Robert Gentz, Rubin Ritter, 14W, 20VC, Adjacent, Alumni Ventures, Alven.
Resilience has raised $826.0M across 4 funding rounds. Most recently, it raised $25.0M Venture Round in May 2024.